Lava Therapeutics N.V.

Lava Therapeutics N.V. company information, Employees & Contact Information

At LAVA, we are focused on applying our expertise in gamma-delta T-cell engagers (TCEs) to transform cancer therapy. We refer to our compounds as gamma-delta bispecific T-cell engagers, or gamma-delta bsTCEs. Our platform generates therapeutics that specifically activate a unique and relatively abundant effector gamma-delta T-cell subset called Vγ9Vδ2 (Vgamma9-Vdelta2) T-cells that have the ability to trigger activity of immune cells of both the innate and adaptive immune system. Our gamma-delta bsTCEs have demonstrated superior efficacy and safety profiles compared to other bsTCE approaches in preclinical studies and show preferential activity against tumor cells thereby potentially limiting toxicity in healthy tissue. To date, we are the only company developing bispecific gamma-delta T-cell engaging antibodies for the treatment of cancer. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor specific antigen CD1d, which can be overexpressed in multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML), among other tumor types. LAVA-051 will enter a Phase I/IIa study in 1Q21.

Company Details

Employees
36
Founded
-
Address
Yalelaan 60, 5th Floor,united States
Phone
+31 8 506 573 44
Email
in****@****ics.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Utrecht, Utrecht
Looking for a particular Lava Therapeutics N.V. employee's phone or email?

Lava Therapeutics N.v. Questions

News

LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025 - GlobeNewswire

LAVA Therapeutics to Move Extraordinary General Meeting to Early November 2025 GlobeNewswire

Biotech Deal Update: LAVA Therapeutics Postpones XOMA Acquisition Vote to Address Cash Position - Stock Titan

Biotech Deal Update: LAVA Therapeutics Postpones XOMA Acquisition Vote to Address Cash Position Stock Titan

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation - GlobeNewswire

LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation GlobeNewswire

LAVA Therapeutics Enters Agreement to Be Acquired by XOMA Royalty Corporation and Announces Discontinuation of LAVA-1266 Development - Quiver Quantitative

LAVA Therapeutics Enters Agreement to Be Acquired by XOMA Royalty Corporation and Announces Discontinuation of LAVA-1266 Development Quiver Quantitative

LAVA Reports First Quarter 2025 Financial Results, Provides Business Update - Yahoo Finance

LAVA Reports First Quarter 2025 Financial Results, Provides Business Update Yahoo Finance

Development of LAVA-1207 Discontinues in mCRPC - OncLive

Development of LAVA-1207 Discontinues in mCRPC OncLive

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers - GlobeNewswire

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers GlobeNewswire

LAVA Therapeutics N.V. Announces Pipeline Reprioritization and Strategic Focus on LAVA-1266 with Continued Support for Partnered Programs - Quiver Quantitative

LAVA Therapeutics N.V. Announces Pipeline Reprioritization and Strategic Focus on LAVA-1266 with Continued Support for Partnered Programs Quiver Quantitative

$1.04 per share: XOMA Royalty & LAVA amend purchase agreement, add up to $0.23 CVR - Stock Titan

$1.04 per share: XOMA Royalty & LAVA amend purchase agreement, add up to $0.23 CVR Stock Titan

LAVA Therapeutics Agrees to XOMA Buyout Deal as Cancer Drug Development Halts - Stock Titan

LAVA Therapeutics Agrees to XOMA Buyout Deal as Cancer Drug Development Halts Stock Titan

LAVA Announces Clinical Development Milestone Achieved by - GlobeNewswire

LAVA Announces Clinical Development Milestone Achieved by GlobeNewswire

Vδ2 T-cell engagers bivalent for Vδ2-TCR binding provide anti-tumor immunity and support robust Vγ9Vδ2 T-cell expansion - Frontiers

Vδ2 T-cell engagers bivalent for Vδ2-TCR binding provide anti-tumor immunity and support robust Vγ9Vδ2 T-cell expansion Frontiers

Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future - Frontiers

Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future Frontiers

Seagen and LAVA Therapeutics Announce Exclusive Worldwide - GlobeNewswire

Seagen and LAVA Therapeutics Announce Exclusive Worldwide GlobeNewswire

LAVA Therapeutics Presents Initial LAVA-051 Clinical Data at the ESMO Targeted Anticancer Therapies Congress 2022 - GlobeNewswire

LAVA Therapeutics Presents Initial LAVA-051 Clinical Data at the ESMO Targeted Anticancer Therapies Congress 2022 GlobeNewswire

LAVA Therapeutics Announces Participation at Upcoming Scientific Conferences - GlobeNewswire

LAVA Therapeutics Announces Participation at Upcoming Scientific Conferences GlobeNewswire

LAVA Therapeutics to Present Initial Phase 1/2a Clinical - GlobeNewswire

LAVA Therapeutics to Present Initial Phase 1/2a Clinical GlobeNewswire

Top Lava Therapeutics N.V. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant